問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
Find Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
鄭景泉
下載
2023-10-16 - 2027-06-30
Condition/Disease
Test Drug
Participate Sites11Sites
Recruiting11Sites
2024-01-01 - 2025-12-31
Participate Sites9Sites
Recruiting7Sites
Terminated2Sites
2024-08-01 - 2028-11-05
Participate Sites4Sites
Recruiting4Sites
2023-06-01 - 2030-05-31
Recruiting9Sites
2023-07-01 - 2030-06-30
Participate Sites8Sites
Recruiting8Sites
2022-03-01 - 2026-12-31
2024-10-01 - 2034-06-01
Participate Sites5Sites
Recruiting5Sites
2025-01-15 - 2032-12-01
Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and with Tumor Cell PD-L1 expression of 1% to 49%
Relatlimab & Nivolumab Fixed Dose Vial (BMS-986213)
Participate Sites2Sites
Recruiting2Sites
2021-06-01 - 2023-12-31
全部
